INFLIXIMAB IN THE TREATMENT OF SEVERE STEROID-REFRACTORY ULCERATIVE COLITIS – A CASE REPORT

INFLIXIMAB IN THE TREATMENT OF SEVERE STEROID-REFRACTORY ULCERATIVE COLITIS – A CASE REPORT

<p>Background. The natural course of ulcerative colitis (UC) can be complicated with an acute severe attack of high degree of activity of inflammation which represents a life-threatening condition. High-dose intravenous steroids have been the treatment of choice for induction of clinical remis...

Full description

Bibliographic Details
Main Authors:	Darja Urlep, Jernej Dolinšek, Dušanka Mičetič Turk
Format:	Article
Language:	English
Published:	Slovenian Medical Association 2004-04-01
Series:	Zdravniški Vestnik
Subjects:	steroid-resistant ulcerative colitis fulminant attack therapy infliximab
Online Access:	http://vestnik.szd.si/index.php/ZdravVest/article/view/2275

Similar Items

Comparable Long-Term Outcomes of Cyclosporine and Infliximab in Patients With Steroid-Refractory Acute Severe Ulcerative Colitis: A Meta-Analysis
by: Kata Szemes, et al.
Published: (2020-01-01)

Infliximab induces clinical, endoscopic and histological responses in refractory ulcerative colitis Infliximab induce respuesta clínica, endoscópica e histológica en la colitis ulcerosa refractaria
by: F. Bermejo, et al.
Published: (2004-02-01)

Promising effect of infliximab on the extent of involvement in ulcerative colitis
by: Peyman Adibi, et al.
Published: (2011-01-01)

The Effect of Infliximab on Patients with Ulcerative Colitis in Korea
by: Hyun Il Seo, et al.
Published: (2014-07-01)

Long-term infliximab therapy for ulcerative colitis in real clinical practice
by: O V Knyazev, et al.
Published: (2016-08-01)

Pyoderma gangrenosum associated with ulcerative colitis: response to infliximab Pioderma gangrenoso asociado a colitis ulcerosa: respuesta a infliximab
by: A. López San Román, et al.
Published: (2004-06-01)

A pharmacokinetic approach to model-guided design of infliximab schedules in ulcerative colitis patients
by: Alejandro Pérez-Pitarch, et al.
Published: (2015-03-01)

Has infliximab influenced the course and prognosis of acute severe ulcerative colitis?
by: Viscido A, et al.
Published: (2019-04-01)

Early Serum Infliximab Levels in Pediatric Ulcerative Colitis
by: Jennifer C. C. deBruyn, et al.
Published: (2021-07-01)

Long-term outcomes of infliximab in a real-world multicenter cohort of patients with acute severe ulcerative colitis
by: Shin Ju Oh, et al.
Published: (2021-07-01)

Management and treatment of distal ulcerative colitis
by: Andrea Calafiore, et al.
Published: (2013-12-01)

Febrile Neutropenia with Thrombocytopenia after Infliximab Induction in a Patient with Ulcerative Colitis
by: Gustavo Gomez, et al.
Published: (2016-10-01)

Noninvasive biomarkers as surrogate predictors of clinical and endoscopic remission after infliximab induction in patients with refractory ulcerative colitis
by: Elham A Hassan, et al.
Published: (2017-01-01)

Short-Term Response to Infliximab in Rheumatoid Pattern Polyarthropathy Complicating Ulcerative Colitis
by: ilke Coskun Benlidayi, et al.
Published: (2015-12-01)

Long-term results of medical treatment in patients with a severe attack of ulcerative colitis
by: I L Khalif, et al.
Published: (2015-02-01)

Autoimmune hemolytic anemia associated with infliximab infusion in ulcerative colitis
by: Fazia A. Mir, et al.
Published: (2018-02-01)

Association between serum tumor necrosis factor-alpha level and the efficacy of infliximab for refractory pouchitis after restorative proctocolectomy in patients with ulcerative colitis
by: Motoi Uchino, et al.
Published: (2017-10-01)

The efficacy and safety of infliximab and calcineurin inhibitors in steroid-refractory UC patients: A meta-analysis
by: Heng-Nan Zhao, et al.
Published: (2021-01-01)

Calprotectin and the Magnitude of Antibodies to Infliximab in Clinically-stable Ulcerative Colitis Patients are More Relevant Than Infliximab Trough Levels and Pharmacokinetics for Therapeutic Escalation
by: Fernando Magro, et al.
Published: (2017-07-01)

Efficacy of Infliximab Dose Escalation in Patients with Refractory Immunotherapy-Related Colitis: A Case Series
by: Faleck, D.M, et al.
Published: (2022)

Cost-Effectiveness Analysis of Vedolizumab Compared With Infliximab in Anti-TNF-α-Naïve Patients With Moderate-to-Severe Ulcerative Colitis in China
by: Ting Zhou, et al.
Published: (2021-08-01)

Evaluation of efficacy and comparative frequency of adverse events in patients with ulcerative colitis receiving the original infliximab and its biosimilar. One year of observation
by: O V Knyazev, et al.
Published: (2019-08-01)

A comparison of short-term therapeutic efficacy between infliximab and tacrolimus for moderate to severe ulcerative colitis
by: Yamagami Hirokazu, et al.
Published: (2017-09-01)

Outcomes of a National Cohort of Children with Acute Severe Ulcerative Colitis
by: Abisoye O. Akintimehin, et al.
Published: (2018-03-01)

Clinical management of severe active ulcerative colitis in the TNF-a inhibitors era
by: Andrea Calafiore, et al.
Published: (2013-12-01)

Infliximab for pediatric patients with ulcerative colitis: a phase 3, open-label, uncontrolled, multicenter trial in Japan
by: Hitoshi Tajiri, et al.
Published: (2019-10-01)

Multidrug-resistant Disseminated Tuberculosis Related to Infliximab in a Patient with Ulcerative Colitis and Negative Evaluation for Latent Tuberculosis
by: Yu Kyung Jun, et al.
Published: (2019-09-01)

Simultaneous Onset of Ulcerative Colitis and Disseminated Pyoderma Gangrenosum
by: Albrecht Neesse, et al.
Published: (2007-10-01)

Dramatic Deep and Durable Remission of Acute Fulminant Ulcerative Colitis Achieved with Cyclosporine in a Patient Who Failed the Induction Intravenous Phase of Cyclosporine
by: Alicia Philippou, et al.
Published: (2021-02-01)

Long-term outcomes of immunosuppression - naïve steroid responders following hospitalization for acute severe ulcerative colitis
by: Vedamurthy, Amar
Published: (2018)

Pyoderma Vegetans Associated with Ulcerative Colitis: A Case with Good Response to Steroids
by: Filiz Canpolat, et al.
Published: (2011-03-01)

Case Presentation: a Facial Ulceration in a Patient with Ulcerative Colitis
by: Andreea GHIDERSA, et al.
Published: (2020-09-01)

Infliximab use in ulcerative colitis flare with clostridium difficile infection: A report of two cases and literature review
by: Bhupinder S. Romana, et al.
Published: (2018-09-01)

Loss of response and frequency of adverse events in patients with ulcerative colitis and Crohn’s disease when switching from the original infliximab to its biosimilars
by: O. V. Knyazev, et al.
Published: (2021-02-01)

Platelet indices as potential biomarkers for determining active ulcerative colitis and assessing the efficacy of biological treatment – experience of a single centre – a pilot study
by: Michalak Agata, et al.
Published: (2019-12-01)

Frequency, predictors, and consequences of maintenance infliximab therapy intensification in ulcerative colitis
by: Luis Fernández-Salazar, et al.
Published: (2015-09-01)

Golimumab Therapy in Ulcerative Colitis
by: Won Moon
Published: (2016-02-01)

Novel Gene Signatures Predicting Primary Non-response to Infliximab in Ulcerative Colitis: Development and Validation Combining Random Forest With Artificial Neural Network
by: Jing Feng, et al.
Published: (2021-09-01)

Efficacy And Safety Of Adalimumab Biosimilar (Exemptia) In Moderate-To-Severe Steroid-Refractory Ulcerative Colitis Patients: Real-Life Outcomes In Resource-Constrained Setting At 24-Weeks Follow-Up
by: Chandra A, et al.
Published: (2019-11-01)

A Novel Neutrophil-Based Biomarker to Monitor Disease Activity and Predict Response to Infliximab Therapy in Patients With Ulcerative Colitis
by: Gao, C., et al.
Published: (2022)